Eric R. Fearon, M.D., Ph.D.
Emanuel N Maisel Professor of Oncology
Director, University of Michigan Comprehensive Cancer Center
Professor of Internal Medicine, Human Genetics, & Pathology
Chief, Molecular Medicine & Genetics Division, University of Michigan Medical School
Fearon was named director of the University of Michigan Comprehensive Cancer Center in 2016. He has served as the Emanuel N. Maisel Professor of Oncology and was appointed associate director for basic science research at the Cancer Center in 1995. He also served as deputy director, from 2005-2016.
Fearon received his undergraduate, medical and doctorate degrees from Johns Hopkins University. Prior to joining the faculty at the University of Michigan, he was a faculty member at Yale University School of Medicine. He holds the title of professor in the departments of Internal Medicine, Human Genetics and Pathology at the University of Michigan Medical School. In 2010, Fearon was appointed division chief for the Molecular Medicine and Genetics Division in the Department of Internal Medicine.
Fearon has authored more than 135 peer-reviewed research manuscripts and more than 60 review/editorial articles and book chapters. He has pursed research in the cancer genetics field, particularly investigations of selected gene defects that underlie colon and rectal tumor development and progression to advanced stages. He has served on the editorial boards of various journals in the cancer biology and human genetics fields and currently is an editorial board member or editor for a number of journals, including The Journal of Biological Chemistry, Current Biology, Journal of Clinical Investigation, Gastroenterology, and Molecular Cancer Research. In addition, he has served as a member or chair of various National Institutes of Health and National Cancer Institute advisory groups and grant review committees, including the Panel to Investigate the NIH Investment in Gene Therapy, the National Cancer Institute Board of Scientific Advisors, and the NIH Pathology B and Cancer Genetics Study Sections.
Fearon’s honors include election to the American Society for Clinical Investigation (where he served as vice president, president-elect and president), the Association of American Physicians, the Johns Hopkins University Society of Scholars and the National Academy of Medicine.
Other University of Michigan Comprehensive Cancer Center Leaders
Pavan Reddy, M.D., deputy director
Reddy is the Moshe Talpaz Professor of Translational Oncology, professor of internal medicine and interim division chief of hematology-oncology at the U-M Medical School. Reddy received his medical degree from Osmania Medical College in India and completed fellowships in hematology-oncology and blood and marrow transplantation at the University of Michigan, where he joined the faculty in 2003. Reddy’s research focuses on understanding the biology and finding ways to prevent or treat graft-vs.-host disease following allogeneic hematopoietic stem cell transplant. His research is funded by several NIH grants. As an investigator, he has turned some of his laboratory discoveries into clinical trials testing potential new therapies in patients. He is an elected member of the Association of American Physicians, American Society of Clinical Investigators and American Clinical and Climatological Association. He holds leadership roles in multiple scientific committees for the American Society of Hematology and the American Society of Blood and Marrow Transplantation and serves on NIH panels. He is an associate editor for the journals Hematologica, Biology of Blood and Marrow Transplantation, and Bone Marrow Transplantation
Elizabeth Lawlor, M.D., Ph.D., associate director for education and training
Lawlor is the Russell G. Adderley Professor of Pediatric Oncology Research and an associate professor of pediatrics and pathology at the U-M Medical School. She received her medical degree from McMaster University in Ontario, Canada, and her doctorate in cancer biology from the University of British Columbia in Vancouver, Canada. She completed clinical and research fellowships in pediatric hematology/oncology and bone marrow transplantation at British Columbia Children's Hospital, and post-doctoral training at the University of California San Francisco Cancer Research Institute. She joined the University of Michigan faculty in 2010 from Children’s Hospital Los Angeles and the University of Southern California. Lawlor’s research focuses on understanding how hijacking of normal stem cell and developmental processes contributes to the initiation and progression of Ewing sarcoma.
Bhramar Mukherjee, Ph.D., associate director for cancer control and population sciences.
Mukherjee is John D. Kalbfleisch Collegiate Professor of Biostatistics, associate chair of biostatistics and professor of epidemiology at the U-M School of Public Health. She joined the university in 2006. Mukherjee completed her doctorate in statistics at Purdue University. Her principal research interests lie in the intersection of genetic and environmental epidemiology. Cancer research interests include penetrance estimation in high risk cancer families, studies of gene-environment interaction, characterizing and distinguishing molecular sub-types of cancer and joint analysis of electronic health records and genomics data with a focus on cancer outcomes. She is a fellow of the American Statistical Association, an elected senior fellow for the Michigan Society of Fellows and recipient of the 2016 Gertrude Cox award for outstanding contribution to biostatistics by a mid-career investigator. She has co-authored more than 160 publications in statistics, biostatistics, epidemiology, environmental health and cancer. As co-director of the Global Health Statistics Core at the School of Public Health, she remains heavily engaged in global health research.
Alnawaz Rehemtulla, Ph.D., associate director for shared resources
Rehemtulla is the Ruth Tuttle Freeman Professor of Radiation Oncology and Director of the Division of Molecular Imaging. Rehemtulla joined the University of Michigan faculty in 1994. He received his doctorate degree in immunology from the University of Calgary in Canada and did postdoctoral fellowships at the Scripps Clinic and Research Foundation in LaJolla, Calif., and the Genetics Institute in Cambridge, Mass. Rehemtulla’s research interests include molecular imaging, mouse models of cancer, and the discovery and development of therapeutic molecules. He holds five patents and has more than 200 peer-reviewed publications.
Anne Schott, M.D., associate director for clinical research
Schott is a clinical professor of hematology/oncology at the U-M Medical School. She received her medical degree from the University of South Alabama and completed a fellowship at the University of Michigan, joining the faculty in 1996. Schott treats patients with breast cancer and is an active clinical trialist, working with laboratory researchers to translate and test potential novel treatments in patients with breast cancer. She serves as a principal investigator on multiple clinical trials. An active member of the National Clinical Trials Network, Schott serves as deputy chair of SWOG and vice chair of NCTN Research in SWOG. She is chair of the board of directors of the Hope Foundation, a public charity that supports cancer research, education and patient advocacy as it relates to SWOG.
Moshe Talpaz, M.D., associate director for translational research
Talpaz is the Alexander J. Trotman Professor of Leukemia Research and associate chief of hematology/oncology at the U-M Medical School. A leading clinical investigator in hematologic malignancies, Talpaz brings special expertise in immunotherapy, cytokines and biologic response modifiers. Internationally known for his role in the development of targeted cancer therapeutics, Talpaz pioneered the study of interferon in chronic myelogenous leukemia, which was the first line therapy for CML until the introduction of Gleevec. As a pivotal member of the team that developed Gleevec, Talpaz was instrumental in bringing to market one of the most effective targeted treatments used to date in cancer care. Talpaz joined University of Michigan in 2006 from M.D. Anderson Cancer Center in Houston. He has authored or co-authored nearly 400 articles in top national journals and textbooks.
Jeremy M. G. Taylor, Ph.D., associate director for biostatistics
Taylor is the Pharmacia Research Professor of Biostatistics at the U-M School of Public Health and a professor of radiation oncology, computational medicine and bioinformatics at the U-M Medical School. He received his doctorate in statistics from the University of California Berkeley. He came to the University of Michigan in 1998 from the University of California Los Angeles. Taylor has had visiting positions at the Medical Research Council in Cambridge, England; the University of Adelaide in Australia; INSERM in Bordeaux, France; and CSIRO in Sydney, Australia. He has worked in various areas of statistics and biostatistics research, including Box-Cox transformations, longitudinal and survival analysis, cure models, missing data, causal inference, clinical trial design, surrogate and auxiliary variables. He has been heavily involved in collaborations in the areas of radiation oncology, cancer research and bioinformatics.
Stephen J. Weiss, M.D., associate director for basic science research
Weiss is the E. Gifford and Love Barnett Upjohn Professor of Medicine and Oncology. He is one of 25 researchers who comprise the U-M Life Sciences Institute. Weiss joined the University of Michigan faculty in 1982 from Washington University. He received his medical degree from Ohio State University. Weiss has served as division chief of molecular medicine and genetics and interim director of the Life Sciences Institute. Weiss’ research efforts focus on the mechanisms used by cancer cells to remodel tissue structure during tumor progression, invasion and metastasis. He is a member of the American Society of Clinical Investigation, the Association of American Physicians, National Academy of Medicine of the National Academy of Sciences and served as the past editor-in-chief of the Journal of Clinical Investigation.